JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Uranium Bull Market Gains Momentum Amid Supply Deficits and Geopolitical Tensions 
Dollar Retreats as Strait of Hormuz Reopens, Easing Safe-Haven Demand 
Japan Eyes Private Credit as Key Pillar in New Financial Strategy 
Stocks Surge as Strait of Hormuz Reopens, Oil Prices Plunge 
Energy Price Spike Won't Trigger Lasting Inflation, Analysts Say 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
U.S. Stock Futures Fall as Iran Tensions Escalate and Oil Prices Surge 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Oil Prices Dip as Middle East Peace Hopes Grow Amid Iran-U.S. Talks 
This fuel crisis could last for a while. It’s time for a new approach to fuel use - end it 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
U.S. Stock Futures Hold Steady After S&P 500 and Nasdaq Hit Record Highs 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
